Answers are grounded in this paper and cite their sources.
Clinical review highlights frequent diarrhoea from tyrosine kinase inhibitors in metastatic renal cell carcinoma, indicating a need for mechanistic insights.
The antiangiogenic tyrosine kinase inhibitors (TKIs) sunitinib, pazopanib, axitinib and cabozantinib have transformed management and lengthened survival of patients with metastatic renal cell carcinoma [1]: 12% now survive more than 5 years [1]. TKIs are taken long-term, until disease progression or intolerable toxicity [1], so even low grade adverse effects may detract from quality of life. Diarrhoea is a common TKI-related toxicity; reported rates of all grades are 55%–65%. However, the causative mechanism is unclear.
No takes yet. Share an insight, caveat, or question.
Lightowlers et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: